Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

Inclusion Criteria:

• Postmenopausal women defined as women who have stopped having menstrual periods

• Written informed consent to participate in the trial

• Biopsy confirmation of invasive breast cancer

• Evidence of hormone sensitivity

• Willingness to undergo biopsies

Exclusion Criteria:

• Any previous treatment for breast cancer

• Unwillingness to stop taking any drug known to affect sex hormonal status or a patientin which it would be inappropriate to stop.

• Any severe concurrent condition that would preclude surgery or that would jeopardizecompliance with the study, e.g., uncontrolled cardiac disease or uncontrolled diabetesmellitus

• The presence of more than one primary tumor

• History of hypersensitivity to castor oil

• History of known bleeding disorders